Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Abstract Text:

Charles D Blanke,Cathryn Rankin,George D Demetri,Christopher W Ryan,Margaret von Mehren,Robert S Benjamin,A Kevin Raymond,Vivien H C Bramwell,Laurence H Baker,Robert G Maki,Michael Tanaka,J Randolph Hecht,Michael C Heinrich,Christopher D M Fletcher,John J Crowley,Ernest C Borden,Charles D Blanke,Cathryn Rankin,George D Demetri,Christopher W Ryan,Margaret von Mehren,Robert S Benjamin,A Kevin Raymond,Vivien H C Bramwell,Laurence H Baker,Robert G Maki,Michael Tanaka,J Randolph Hecht,Michael C Heinrich,Christopher D M Fletcher,John J Crowley,Ernest C Borden,

PURPOSE: To assess potential differences in progression-free or overall survival when imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors (GIST) at a standard dose (400 mg daily) versus a high dose (400 mg twice daily). PATIENTS AND METHODS: Patients with metastatic or surgically unresectable GIST were eligible for this phase III open-label clinical trial. At registration, patients were randomly assigned to either standard or high-dose imatinib, with close interval follow-up. If objective progression occurred by Response Evaluation Criteria in Solid Tumors, patients on the standard-dose arm could reregister to the trial and receive the high-dose imatinib regimen. RESULTS: Seven hundred forty-six patients with advanced GIST from 148 centers across the United States and Canada were enrolled onto this trial in 9 months. With a median follow-up of 4.5 years, median progression-free survival was 18 months for patients on the standard-dose arm, and 20 months for those receiving high-dose imatinib. Median overall survival was 55 and 51 months, respectively. There were no statistically significant differences in objective response rates, progression-free survival, or overall survival. After progression on standard-dose imatinib, 33% of patients who crossed over to the high-dose imatinib regimen achieved either an objective response or stable disease. There were more grade 3, 4, and 5 toxicities noted on the high-dose imatinib arm. CONCLUSION: This trial confirms the effectiveness of imatinib as primary systemic therapy for patients with incurable GIST but did not show any advantage to higher dose treatment. It appears reasonable to initiate therapy with 400 mg daily and to consider dose escalation on progression of disease.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Publishing Authors By Initials

CD Blanke,C Rankin,GD Demetri,CW Ryan,M von Mehren,RS Benjamin,AK Raymond,VH Bramwell,LH Baker,RG Maki,M Tanaka,JR Hecht,MC Heinrich,CD Fletcher,JJ Crowley,EC Borden,CD Blanke,C Rankin,GD Demetri,CW Ryan,M von Mehren,RS Benjamin,AK Raymond,VH Bramwell,LH Baker,RG Maki,M Tanaka,JR Hecht,MC Heinrich,CD Fletcher,JJ Crowley,EC Borden,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of clinical oncology : official journal of

VOLUME: 26

Page Numbers: 626-32

Journal Abbreviation: J. Clin. Oncol.

ISSN: 1527-7755

DAY: 1

MONTH: Feb

YEAR: 2008

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309333

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

AFFILIATION: Oregon Health & Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, L-586, Portland, OR 97239, USA. blankec@ohsu.edu

Country: United States

AGENCY: United States NCI

GRANT: U01-CA70172-01

ACRONYM: CA

MEDLINETA: J Clin Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 Related Publications

• Aggressive angioblastic meningioma with multiple sites in the neural axis.
• Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma.
• Calculations find that tunneling plays a major role in the reductive elimination of methane from hydridomethylbis(trimethylphosphine)platinum: how to confirm this computational prediction experimentally.
• Calculations of the Effect of Tunneling on the Swain-Schaad Exponents (SSEs) for the 1,5-Hydrogen Shift in 5-Methyl-1,3-cyclopentadiene. Can SSEs Be Used to Diagnose the Occurrence of Tunneling?
• Cap-free structure of eIF4E suggests a basis for conformational regulation by its ligands.
• Concurrent bioremediation of perchlorate and 1,1,1-trichloroethane in an emulsified oil barrier.
• Effect of microstructure on molecular oxygen permeation through condensed phospholipid monolayers.
• Effective distribution of emulsified edible oil for enhanced anaerobic bioremediation.
• G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.
• Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810).
• Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.
• Immunological effects of levamisole in vitro.
• Immunoregulatory properties of ISG15, an interferon-induced cytokine.
• In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine.
• Melanoma 2007: current state and preview of the future.
• Oral haemorrhage.
• Patient education and the quality assurance process.
• Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
• Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
• Production of ISG-15, an interferon-inducible protein, in human corneal cells.
• RING fingers and B-boxes: zinc-binding protein-protein interaction domains.
• Regularization of noisy ISAR images containing extended features.
• Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.
• Successful thrombolysis in the vertebrobasilar artery after endovascular occlusion of a recently ruptured large basilar tip aneurysm.
• The circulation time from the pulmonary artery to the femoral artery and the quantity of blood in the lungs in normal individuals.
• The eIF4E RNA regulon promotes the Akt signaling pathway.
• The mechanism of shock in peritonitis; a study of the hemodynamics of shock occurring in peritonitis experimentally produced in dogs.
• Tungsten filament material and cesium dynamic equilibrium effects on a surface converter ion source.
• Very-Low-Lying Electronic States Result from n --> pi Excitations in Open-Shell Annulenes, Annelated with alpha-Dicarbonyl Groups.
• eIF4E is a central node of an RNA regulon that governs cellular proliferation.